Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ) Stock
—
Valuation
Financials & Margins
Valuation & Return Ratios
Ownership
About Hunan Er-Kang Pharmaceutical Co., Ltd
—
Hunan Er-Kang Pharmaceutical Co., Ltd is led by CEO Qingrong Sun, employs 1,271 people, headquartered in Changsha, CN, publicly traded since 2011.
Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ) stock trades at $2.76 with a market capitalization of $6.68B. The stock is valued at a negative price-to-earnings (P/E) ratio of -18.00, reflecting a net loss over the last twelve months, price-to-book of 1.66, price-to-sales of 6.36. Over the past 52 weeks the stock has ranged between $2.72 and $5.11, and currently trades 46.0% below its 52-week high.
On profitability, Hunan Er-Kang Pharmaceutical Co., Ltd generates a return on equity (ROE) of -9.42% (negative, reflecting a net loss), an operating margin of 8.95%, a net profit margin of -35.47%.
Official website: www.hnerkang.com
Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ) — frequently asked questions
What is Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ) stock price today?
Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ) is currently trading at $2.76, down 8.91% today.
What is 300267.SZ P/E ratio?
Hunan Er-Kang Pharmaceutical Co., Ltd's P/E ratio is -18.00. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.
What is 300267.SZ return on equity (ROE)?
Hunan Er-Kang Pharmaceutical Co., Ltd's return on equity (ROE) is -9.42%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.
What is Hunan Er-Kang Pharmaceutical Co., Ltd's market cap?
Hunan Er-Kang Pharmaceutical Co., Ltd has a market capitalization of $6.68B.
Does 300267.SZ pay a dividend?
Hunan Er-Kang Pharmaceutical Co., Ltd is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does 300267.SZ carry?
Hunan Er-Kang Pharmaceutical Co., Ltd has a debt-to-equity ratio of 0.18. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is 300267.SZ's profit margin?
Hunan Er-Kang Pharmaceutical Co., Ltd reports a net profit margin of -35.47% — the share of revenue left after every cost, including tax and interest.
What sector is 300267.SZ in?
Hunan Er-Kang Pharmaceutical Co., Ltd is classified under —, in the — industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is 300267.SZ listed on?
Hunan Er-Kang Pharmaceutical Co., Ltd trades on SHZ under the ticker 300267.SZ.
What is 300267.SZ's 52-week range?
Over the last year Hunan Er-Kang Pharmaceutical Co., Ltd has traded between $2.72 and $5.11.
Related — Stocks
Popular Stocks
Screens 300267.SZ currently matches
On the figures above, Hunan Er-Kang Pharmaceutical Co., Ltd passes the filters for 10 of our ready-made screens, among them Low Debt Stocks, Day Losers Stocks, Penny Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.